An at-home device the size of a deck of cards now hands 200,000 people the kind of fertility data that used to require a clinic, a blood draw, and a week of waiting.
It's six in the morning somewhere, and someone is peeing on a wand. Not to get a yes or no. To get a number. The wand goes into a small white reader, the reader talks to a phone, and a few minutes later the phone returns four numbers: LH, E3G, PdG, FSH. That is Mira in 2026 - a hormone laboratory the size of a cinnamon roll, sitting on a bathroom shelf in 40+ countries.
Mira is a women's health company that builds the connected hardware, the chemistry, and the AI that interprets it. The device reads quantitative hormone values from urine using fluorescent immunochromatography - the boring, beautiful technology that also powers clinical labs. The app turns those values into a chart your OB-GYN can read. The company has 140-ish people, $8.8M in venture funding, and an unusually loyal user base of more than 200,000 women.
For most of the twentieth century, the hormonal lives of half the species were tracked with a calendar and a thermometer. In the twenty-first, they were tracked with apps that pulled predictions out of averages and called it personalization. None of it actually measured anything.
The truth, inconveniently, is that hormones do not behave like calendars. Cycles vary. PCOS hides in subtypes. Perimenopause sneaks in over a decade. Two people with identical 28-day cycles can ovulate eight days apart. The standard answer was: go to a clinic, get a blood draw, repeat it tomorrow, and the day after that, and the day after that. Almost nobody does this.
That gap - between what your body is doing and what you are allowed to know about it - is the thing Mira was built to close.
Sylvia Kang's first career was the piano. Conservatory training, the works. She switched to biomedical engineering - the kind of switch that on paper looks improbable and in practice mostly means trading one set of obsessive rehearsals for another. She landed in the world of medical device design, where she noticed that the most sensitive diagnostics in the world were locked behind appointments most women could not get.
In 2016, Kang co-founded Mira with Zheng Yang. The bet was specific and a little contrarian: people would pay for hardware - not just an app - if the hardware gave them numbers a doctor would trust. The femtech wave at the time was pouring into period-tracking apps. Mira poured into chemistry.
Founders Sylvia Kang, CEO, biomedical engineer, ex-pianist. Zheng Yang, co-founder. The two of them spent the first years explaining to investors that yes, urine, and yes, on purpose.
The Mira Monitor is a Bluetooth analyzer. Single-use wands - Max, Plus, Ultra, Confirm - test combinations of luteinizing hormone, estrogen metabolite (E3G), progesterone metabolite (PdG), and follicle-stimulating hormone. The numbers land in the Mira app, which threads them through an AI model that maps the user's actual cycle - not a model cycle - and predicts the next one.
LH, E3G, PdG, FSH - the four endocrine signals that map ovulation, conception window, and menopause onset.
// quant, not qualitativeMira reports 99% accuracy versus lab reference in clinical trials. The wands use the same chemistry as professional immunoassays.
// per company dataWand in, reader on, kettle for tea, done. Result lands in the app with a value and a trend line.
// fluorescent immunochromatographyTrying-to-conceive, PCOS management, perimenopause & menopause. One device, three radically different problem spaces.
// Mira Clinic + supplementsInventory The thing about Mira's product line is that nobody set out to build four product lines. They built one device and discovered, slowly, that women in their thirties, forties and fifties were all asking it different questions.
Nine years, one bathroom shelf at a time.
Mira's pitch sounds slightly too good. So here is what holds it up: regulatory clearances, a clinical-trial accuracy figure, a six-figure user base, and a quietly growing list of clinicians who now ask new patients whether they have a Mira at home.
Mira's stated mission is not subtle: empower people to understand their hormones with lab-grade precision so they can make decisions about fertility, PCOS, conception and menopause. What is interesting is what the mission omits. It does not promise pregnancy. It does not promise a cure for PCOS. It promises information - the kind of information women have been politely refused for a very long time.
Map the ovulation window with quantitative LH and confirm with PdG. Share the chart with your fertility clinic.
Track hormonal subtypes across full cycles. Identify patterns clinicians can act on, instead of "irregular".
FSH and estrogen patterns across months - early-warning data for a transition that usually arrives unannounced.
Every wand Mira ships - opted-in and anonymized - adds a cycle to one of the largest longitudinal hormone datasets in the world. That data feeds the AI, which feeds the predictions, which improves the next user's experience. It is the dull, virtuous flywheel of any real medical-data company, and it is the unsexy thing that will matter most in five years. Hormonal subtype research, AI-detected PCOS variants, personalized therapy - the field is wide open and Mira is the company sitting on the cleanest dataset.
The skeptical question is fair: can a $200 box really replace a clinic? It cannot. But it can fill the eleven months and three weeks of the year you are not at the clinic, and that is the part the clinic was never going to fix.
It is still six in the morning. The wand still goes into the white box. The phone still hums. But the person holding it now has nine years of company history behind that hum - a pianist who became an engineer, a Series A in Pleasanton, a chemistry trick borrowed from clinical labs, a regulatory file, a six-figure user community, and a chart that an OB-GYN will read at 9 a.m. with a cup of coffee and a nod. Mira's product is small. The thing it actually delivers is not.